ACP
WINT

Acuta Capital Partners’s Windtree Therapeutics Inc WINT Stock Holding History

Acuta Capital Partners’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28,082
Closed -$468K – 68
2015
Q1 		$468K Buy
+28,082
New +$553K 0.39% 43

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TI
Turner Investments Berwyn, Pennsylvania $134K AUM 49.03% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acuta Capital Partners's WINT Position: Q2 2015 in Review

Acuta Capital Partners sold out of Windtree Therapeutics Inc (WINT) in Q2 2015, closing a stake of 28,082 shares — an estimated $468K sold.

Acuta Capital Partners first reported a position in WINT in Q1 2015 and held it in 1 quarter. The position peaked at $468K in Q1 2015. 52 funds tracked by Wall St. Rank hold WINT as of Q2 2015.

  • Acuta Capital Partners reported no remaining Windtree Therapeutics Inc position as of Q2 2015 after selling out during the quarter.
  • Acuta Capital Partners sold 28,082 Windtree Therapeutics Inc shares in Q2 2015, an estimated $468K.
  • Acuta Capital Partners first reported a position in Windtree Therapeutics Inc in Q1 2015 and held it in 1 quarter.
  • Acuta Capital Partners's Windtree Therapeutics Inc position peaked at $468K in Q1 2015.
  • 52 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q2 2015.

Based on Acuta Capital Partners's 13F filing for Q2 2015, filed 14 Aug 2015.